Literature DB >> 22274926

Assessment of chromosomal imbalances in CIMP-high and CIMP-low/CIMP-0 colorectal cancers.

Joanna Kozlowska1, Pawel Karpinski, Elzbieta Szmida, Izabela Laczmanska, Blazej Misiak, David Ramsey, Marek Bebenek, Wojciech Kielan, Karolina A Pesz, Maria M Sasiadek.   

Abstract

Data presented in a number of recent studies have revealed a negative correlation between CpG island methylator phenotype (CIMP) and chromosomal instability (CIN) measured by a loss of heterozygosity (LOH) of selected loci, suggesting that CIN and CIMP represent two independent mechanisms in sporadic colorectal cancer (CRC) carcinogenesis. However, CIN is a heterogeneous phenomenon, which may be studied not only by employing LOH analysis but also by observing chromosomal imbalances (gains and deletions). The current study aimed to investigate the relationship between CIMP and chromosomal gains and deletions (assessed by comparative genomic hybridization) in a group of 20 CIMP-high and 79 CIMP-low/CIMP-0 CRCs. Our results revealed that the mean numbers of gains and of total chromosomal imbalances were significantly greater (p = 0.004 and p = 0.007, respectively) in the CIMP-low/CIMP-0 group compared to the CIMP-high group, while no significant difference was observed between the mean numbers of losses (p = 0.056). The analysis of copy number changes of 41 cancer-related genes by multiplex ligation-dependent probe amplification showed that CRK gene was exclusively deleted in CIMP-low/CIMP-0 tumors (p = 0.02). Given that chromosomal losses play an important role in tumor suppressor inactivation and chromosomal gains, in the activation of proto-oncogenes, we hypothesize that tumor suppressor inactivation plays similar roles in both CIMP-high and CIMP-low/CIMP-0 CRCs, while the predominance of chromosomal gains in CIMP-low/CIMP-0 tumors may suggest that the activation of proto-oncogenes is the underlying mechanism of CIMP-low/CIMP-0 CRC progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22274926     DOI: 10.1007/s13277-012-0334-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Comparative genomic hybridization based strategy for the analysis of different chromosome imbalances detected in conventional cytogenetic diagnostics.

Authors:  H Tönnies; M Stumm; R D Wegner; I Chudoba; V Kalscheuer; H Neitzel
Journal:  Cytogenet Cell Genet       Date:  2001

2.  Cyclin E and chromosome instability in colorectal cancer cell lines.

Authors:  C Simone; N Resta; L Bagella; A Giordano; G Guanti
Journal:  Mol Pathol       Date:  2002-06

3.  Frequent rearrangements and amplification of the CDX2 homeobox gene in human sporadic colorectal cancers with chromosomal instability.

Authors:  Clément Subtil; Eric Guérin; Anne Schneider; Marie-Pierre Chenard; Elisabeth Martin; Claire Domon-Dell; Isabelle Duluc; Thomas Brabletz; Michèle Kedinger; Bernard Duclos; Marie-Pierre Gaub; Jean-Noël Freund
Journal:  Cancer Lett       Date:  2006-05-30       Impact factor: 8.679

4.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer.

Authors:  Toshinori Hinoue; Daniel J Weisenberger; Christopher P E Lange; Hui Shen; Hyang-Min Byun; David Van Den Berg; Simeen Malik; Fei Pan; Houtan Noushmehr; Cornelis M van Dijk; Rob A E M Tollenaar; Peter W Laird
Journal:  Genome Res       Date:  2011-06-09       Impact factor: 9.043

Review 5.  Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes.

Authors:  Atsushi Kaneda; Koichi Yagi
Journal:  Cancer Sci       Date:  2011-01       Impact factor: 6.716

6.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

Authors:  Ajay Goel; Takeshi Nagasaka; Christian N Arnold; Toru Inoue; Cody Hamilton; Donna Niedzwiecki; Carolyn Compton; Robert J Mayer; Richard Goldberg; Monica M Bertagnolli; C Richard Boland
Journal:  Gastroenterology       Date:  2006-09-20       Impact factor: 22.682

7.  Distinct genetic alterations in colorectal cancer.

Authors:  Hassan Ashktorab; Alejandro A Schäffer; Mohammad Daremipouran; Duane T Smoot; Edward Lee; Hassan Brim
Journal:  PLoS One       Date:  2010-01-26       Impact factor: 3.240

8.  High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers.

Authors:  Naoshi Nishida; Takeshi Nagasaka; Kazuhiro Kashiwagi; C Richard Boland; Ajay Goel
Journal:  Cancer Biol Ther       Date:  2007-04       Impact factor: 4.742

9.  Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation.

Authors:  Richard A Woo; Randy Y C Poon
Journal:  Genes Dev       Date:  2004-06-01       Impact factor: 11.361

10.  Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype.

Authors:  Laura Lentini; Angela Amato; Tiziana Schillaci; Aldo Di Leonardo
Journal:  BMC Cancer       Date:  2007-11-13       Impact factor: 4.430

View more
  3 in total

1.  Customized Array Comparative Genomic Hybridization Analysis of 25 Phosphatase-encoding Genes in Colorectal Cancer Tissues.

Authors:  Izabela Laczmanska; Pawel Skiba; Pawel Karpinski; Marek Bebenek; Maria M Sasiadek
Journal:  Cancer Genomics Proteomics       Date:  2017-01-02       Impact factor: 4.069

2.  Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability.

Authors:  Catherine E Bond; Derek J Nancarrow; Leesa F Wockner; Leanne Wallace; Grant W Montgomery; Barbara A Leggett; Vicki L J Whitehall
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

Review 3.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.

Authors:  Shuji Ogino; Paul Lochhead; Andrew T Chan; Reiko Nishihara; Eunyoung Cho; Brian M Wolpin; Jeffrey A Meyerhardt; Alexander Meissner; Eva S Schernhammer; Charles S Fuchs; Edward Giovannucci
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.